Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Orgenesis Logo
Published on :

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and The Johns Hopkins University, today announce the next phase of their collaboration. This new phase involves construction of a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in Q2 2022 and is expected to be operational in Q2 of 2023.

Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services

Published on :

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

FDA Grants Clearance for Longeviti’s Off-The-Shelf ClearFit® Cover, Accelerating Capability of Ultrasound Imaging after Complex Brain Surgery

Longeviti logo
Published on :

Longeviti Neuro Solutions, developer of the first low-profile intracranial devices that meets the functional and reconstructive needs of brain surgery patients, recently announced that it was granted a 510(k) clearance by the U.S Food and Drug Administration (FDA) for ClearFit® OTS (off-the-shelf).

5 Questions With Bryan Deuber, Biotech Business Development Expert and MPH Student at Johns Hopkins

Photo of Bryan Deuber with his two daughters
Published on :

Since Bryan transitioned from the laboratory to business and corporate development at a global CDMO, he has been interested in improving healthcare for patients in and outside of the clinic by working with internal and external stakeholders involved in the next generation biotherapeutics. Over the years, he has gained insight from various sides of the table through his experience at Johns Hopkins, Morgan Stanley, and, more recently, through the sell-side M&A of Paragon Bioservices to Catalent for $1.2B in May 2019. As director of business development at a stealth biotechnology company, he recently interacted across disciplines, from scientists to CEOs. His experience researching opportunities, gathering intelligence, and organizing teams and data for potential deal execution has allowed him to further develop an extensive network within the BioHealth Capital region to improve healthcare and patient outcomes.

Maryland Commerce Supports Research Professorships at Eight Higher Education Institutions

Published on :

The Maryland Department of Commerce joined eight local colleges and universities in endowing a total of $21.2 million to fund a dozen new research professorships. The endowments were made through the Maryland E-Nnovation Initiative (MEI), a state program created to spur basic and applied research in scientific and technical fields at the colleges and universities. The schools raised a total of more than $10.6 million in private funding for each chair and Maryland Commerce approved matching grants of $10.6 million to support the endowments.

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Published on :

Glyscend, Inc. delivered an oral presentation highlighting preclinical data from a study of its oral proprietary polymer duodenal exclusion therapy during the 57th Annual Meeting of the European Association for the Study of Diabetes on September 28, 2021. Data from earlier results were presented previously this year at the American Diabetes Association 80th Scientific Sessions. Glyscend has also been selected to present at the Obesity Society Annual Meeting in November 2021, focusing on the role of polymer-based duodenal exclusion therapy as an alternative to gastric bypass surgery for the management of obesity.

MyMD Takes on Inflammatory-Related Diseases with MYMD-1

Published on :

While still in the early stages of development, Baltimore’s MyMD Pharmaceuticals lead therapeutic compound MYMD-1 appears to have the potential to be a pipeline in a pill that can play a role in multiple autoimmune and fibrotic diseases where inflammation plays a key role.

Johns Hopkins Technology Ventures Boosts Maryland Life Sciences

Published on :

Johns Hopkins Technology Ventures (JHTV) has had a significant impact on the Maryland life sciences ecosystem since its founding in 2014, assisting with hundreds of licensed therapeutics in development and backing nearly 200 startups that have collectively nearly $3 billion in venture capital funding, 30% of which has remained in the state.

5 Questions with Alia Poonawala, Executive Director, Hire Hopkins

Published on :

Alia Poonawala is the Executive Director of Hire Hopkins, a design-thinking office out of JHU focused on helping companies get access to the best talent possible from across JHU’s 9 divisions. She forms hiring partnerships with companies who are focused on building diversity and equity in their hiring pipelines.

BHCR passes San Francisco in NIH funding

Johns Hopkins University Peabody Research Library
Published on :

The National Institutes of Health provides significant funding for drug development research to universities, companies, and organizations. Over the course of 2020, the NIH provided a significant amount of funding to the BioHealth Capital Region.